We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Noninvasive Alternative to Colonoscopy Wins Partial FDA Approval

By HospiMedica International staff writers
Posted on 18 Feb 2014
Print article
Image: The [US] Food and Drug Administration has approved the PillCam Colon for patients who have experienced an incomplete colonoscopy (Photo courtesy of Given Imaging).
Image: The [US] Food and Drug Administration has approved the PillCam Colon for patients who have experienced an incomplete colonoscopy (Photo courtesy of Given Imaging).
A novel-imaging device that is marketed as a noninvasive alternative to colonoscopy has been cleared for use as a tool to screen the large intestine for polyps and other early signs of colon cancer by the US Food and Drug Administration (FDA).

The Given Imaging Ltd. (Yokneam, Israel) PillCam Colon received clearance for sale in Europe (CE marking) in September 2009 and has been commercially available throughout Europe, Latin America, Canada, and parts of Asia.

The Food and Drug Administration has now approved PillCam Colon for patients who have experienced an incomplete colonoscopy. Given Imaging has estimated that approximately 750,000 patients in the US are not able to complete the colonoscopy procedure each year, due to anatomy issues, previous surgery, or various colon diseases.

Analysts estimate that sales of PillCam Colon could grow to over 60 million USD in North America by 2019, with room for expansion as the technology improves.

"Given's management understands that that traditional colonoscopy is the gastroenterologist's bread and butter right now," said MorningStar (Chicago, IL, USA) analyst Debbie Wang. "So they did not want to do anything that would position this as a substitute. Given's PillCam costs USD 500, significantly less than the USD 4,000 for a colonoscopy. Eventually, doctors may use the device to attract adults who avoid regular screenings due to fears of pain, embarrassment, and general discomfort."

The [US] Centers for Disease Control and Prevention's guidelines currently recommend regular colonoscopies beginning at age 50 and continuing until age 75, though the majority of American adults do not follow the recommendations.

Related Links:

Given Imaging Ltd.
MorningStar


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
12-Channel ECG
CM1200B
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Transvaginal Tube
LiNA McCartney Tube

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.